Related Experiment Videos
[Clinical experience with cefodizime in pediatric field]
T Sekiguchi1, T Okamoto, K Ohara
1Department of Pediatrics, Takamatsu Red Cross Hospital.
Insights
Cefodizime (CDZM) effectively treated bacterial infections in 20 children, with 90% showing good clinical response and all identified bacteria eradicated. This antibiotic demonstrated a favorable safety profile, making it a valuable option for pediatric bacterial infections.
Area of Science:
- Pediatric infectious diseases
- Bacteriology
- Pharmacology
Context:
- Acute bacterial infections in children require effective and safe antibiotic treatments.
- Cefodizime (CDZM) is an antibiotic investigated for pediatric use.
- Previous research may not have fully established CDZM's efficacy and safety in diverse pediatric bacterial infections.
Purpose:
- To evaluate the clinical efficacy and safety of intravenous Cefodizime (CDZM) in pediatric patients with acute bacterial infections.
- To assess the bacteriological eradication rates of identified pathogens following CDZM treatment.
- To determine the incidence of adverse effects associated with CDZM administration in children.
Summary:
- Intravenous Cefodizime (CDZM) was administered to 20 children diagnosed with acute bacterial infections, including tonsillitis, bronchitis, purulent cervical lymphadenitis, urinary tract infections, and pneumonia.
- Clinical efficacy was observed in 18 out of 20 patients (90%), with complete eradication of all 5 identified bacterial strains.
- One case of eosinophilia was the only reported side effect, indicating a generally good safety profile.
Impact:
- Cefodizime (CDZM) shows significant promise as a safe and effective antibiotic for treating a range of bacterial infections in pediatric populations.
- The findings support the use of CDZM in clinical practice for pediatric infectious disease management.
- Further research could explore CDZM's role in specific pediatric infection subtypes and long-term outcomes.
Abstract:
Cefodizime (CDZM, THR-221) was given intravenously to 20 children with the following acute bacterial infections: 2 cases each of tonsillitis, bronchitis, purulent cervical lymphadenitis, and urinary tract infections and 12 cases of pneumonia. Good clinical responses were obtained in 18 patients out of the 20, and bacteriologically, all of the 5 strains identified were eradicated. No side effect was obtained except one case of eosinophilia. From the above clinical results, it is apparent that CDZM is a useful antibiotic for the treatment of pediatric patients with various kinds of bacterial infections.